Mid-term clinical outcomes of new generation drug-eluting stents for treatment of diffuse coronary artery disease.
Çoner A, Çiçek D, Akıncı S, Balcıoğlu S, Altın C, Müderrisoğlu H.
Turk Kardiyol Dern Ars. 2018 Dec;46(8):659-666. doi: 10.5543/tkda.2018.10.5543/tkda.2018.62678.
Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery.
Tsagalou E, Chieffo A, Iakovou I, Ge L, Sangiorgi GM, Corvaja N, Airoldi F, Montorfano M, Michev I, Colombo A.
J Am Coll Cardiol. 2005 May 17;45(10):1570-3. doi: 10.1016/j.jacc.2005.01.049.
Edge-to-Edge Technique to Minimize Ovelapping of Multiple Bioresorbable Scaffolds Plus Drug Eluting Stents in Revascularization of Long Diffuse Left Anterior Descending Coronary Artery Disease.
Rigatelli G, Avvocata FD, Ronco F, Giordan M, Roncon L, Caprioglio F, Grassi G, Faggian G, Cardaioli P.
J Interv Cardiol. 2016 Jun;29(3):275-84. doi: 10.1111/joic.12287.
Impact of the ultra-long 48 mm drug-eluting stent on procedural and clinical outcomes in patients with diffuse long coronary artery disease.
Youn YJ, Jeon HS, Kim YI, Lee JH, Park YJ, Cho DH, Son JW, Lee JW, Ahn MS, Ahn SG, Kim JY, Yoo BS, Lee SH, Yoon J.
Clin Cardiol. 2023 Apr;46(4):416-424. doi: 10.1002/clc.23997. Epub 2023 Feb 20.
Long-term outcomes after stent implantation in very small vessel coronary artery disease.
Liu ES, Yang TH, Tai TH, Chiang CH, Cheng CC, Huang WC, Mar GY, Kuo FY.
Clin Cardiol. 2023 Apr;46(4):431-440. doi: 10.1002/clc.24000. Epub 2023 Feb 23.
Effectiveness and Safety of Zotarolimus-Eluting Stent (Resolute Integrity) in Patients with Diffuse Long Coronary Artery Disease.
Park KH, Ahn Y, Koh YY, Ki YJ, Kim SS, Kim HK, Choi DH, Hong YJ, Hwang JY, Kim DH, Rhew JY, Ryu JK, Park JS, Park TH, Yang TH, Oh SK, Lee BR, Lee SU, Lee SG, Chun KJ, Cho JH, Cha KS, Chae JK, Hur SH, Hwang SH, Park HS, Kim DI.
Korean Circ J. 2019 Aug;49(8):709-720. doi: 10.4070/kcj.2019.0018. Epub 2019 May 15.
Novel ultra-long (48 mm) everolimus-eluting stent for diffusely coronary vessels disease.
Genuardi L, Burzotta F, Russo G, Shoeib O, Verdirosi D, Aurigemma C, Niccoli G, Porto I, Leone AM, Trani C.
Minerva Cardioangiol. 2019 Apr;67(2):87-93. doi: 10.23736/S0026-4725.19.04879-5. Epub 2019 Mar 19.
One-year Outcomes of XIENCE Skypoint 48-mm Drug-Eluting Stents in Long Coronary Lesions: The SPIRIT 48 Trial.
Park KE, Wu CJ, Chehab B, Maksoud A, Bertolet B, Ying SW, Simoes T, Pingle SC, Chang CJ.
J Soc Cardiovasc Angiogr Interv. 2023 May 18;2(4):101001. doi: 10.1016/j.jscai.2023.101001. eCollection 2023 Jul-Aug.
Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
Biondi-Zoccai G, Valgimigli M, Margheri M, Marzocchi A, Lettieri C, Stabile A, Petronio AS, Binetti G, Bolognese L, Bellone P, Sardella G, Contarini M, Sheiban I, Marra S, Piscione F, Romeo F, Colombo A, Sangiorgi G.
Am Heart J. 2012 May;163(5):835.e1-7. doi: 10.1016/j.ahj.2012.02.009.
Intravascular ultrasound-guided percutaneous coronary intervention improves the clinical outcome in patients undergoing multiple overlapping drug-eluting stents implantation.
Ahn SG, Yoon J, Sung JK, Lee JH, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Lee SH, Choe KH.
Korean Circ J. 2013 Apr;43(4):231-8. doi: 10.4070/kcj.2013.43.4.231. Epub 2013 Apr 30.
